WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca

Jun 10, 2008, 01:00 ET from WuXi PharmaTech

    SHANGHAI, China, June 10 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:  
 WX), a leading pharmaceutical, biotechnology and medical device research
 and development outsourcing company with operations in China and the United
 States, announced today that it has signed a new three-year collaboration
 agreement with AstraZeneca.
     (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
     In April 2006, WuXi PharmaTech and AstraZeneca entered into a two-year
 US$14 million collaboration agreement that WuXi PharmaTech successfully
 delivered more than 100,000 compounds two months ahead of schedule.
     "This new collaboration agreement further strengthens our already
 productive relationship with AstraZeneca, and it is the direct result of
 our research capability and firm commitment to quality and customer
 satisfaction," commented Dr. Ge Li, Chairman and Chief Executive Officer of
 WuXi PharmaTech, "We are hopeful that with our strong and growing drug R&D
 capabilities the expansion of our collaboration will help AstraZeneca
 achieve its strategic goals."
     Under the new collaboration agreement WuXi PharmaTech will synthesize
 compounds, according to AstraZeneca's designs, which will further expand
 AstraZeneca's global compound collection.
     "The collaboration with WuXi PharmaTech has exceeded our expectations
 delivering value to AstraZeneca beyond the cost savings in labor and
 materials," said Deborah Hartman, Vice President, Lead Generation Discovery
 Enabling Capabilities and Sciences (DECS), AstraZeneca, "We are looking
 forward to the prospect of building on this success through our expanded
     High Throughput Screening remains a major source of chemical starting
 points, making it important to generate many high quality compounds with
 the proper purity and targeted characteristics. WuXi PharmaTech has
 developed an innovative, scalable and high through put library compound
 synthesis and purification process with an annual capacity of one million
 compounds. Other lead generation services provided by the company include
 designing and synthesizing libraries, as well as templates for library
 synthesis, benchmark compound synthesis and custom synthesis.
     About WuXi PharmaTech
     WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical
 device R&D outsourcing company, with operations in China and the United
 States. As a research-driven and customer-focused company, WuXi PharmaTech
 provides pharmaceutical, biotechnology and medical device companies a broad
 and integrated portfolio of laboratory and manufacturing services
 throughout the drug and medical device R&D process. WuXi PharmaTech's
 services are designed to assist its global partners in shortening the cycle
 and lowering the cost of drug and medical device R&D. For more information,
 please visit: http://www.wuxipharmatech.com .

SOURCE WuXi PharmaTech